Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Sci Rep ; 14(1): 11373, 2024 05 18.
Article in English | MEDLINE | ID: mdl-38762564

ABSTRACT

There are some discrepancies about the superiority of the off-pump coronary artery bypass grafting (CABG) surgery over the conventional cardiopulmonary bypass (on-pump). The aim of this study was estimating risk ratio of mortality in the off-pump coronary bypass compared with the on-pump using a causal model known as collaborative targeted maximum likelihood estimation (C-TMLE). The data of the Tehran Heart Cohort study from 2007 to 2020 was used. A collaborative targeted maximum likelihood estimation and targeted maximum likelihood estimation, and propensity score (PS) adjustment methods were used to estimate causal risk ratio adjusting for the minimum sufficient set of confounders, and the results were compared. Among 24,883 participants (73.6% male), 5566 patients died during an average of 8.2 years of follow-up. The risk ratio estimates (95% confidence intervals) by unadjusted log-binomial regression model, PS adjustment, TMLE, and C-TMLE methods were 0.86 (0.78-0.95), 0.88 (0.80-0.97), 0.88 (0.80-0.97), and 0.87(0.85-0.89), respectively. This study provides evidence for a protective effect of off-pump surgery on mortality risk for up to 8 years in diabetic and non-diabetic patients.


Subject(s)
Coronary Artery Bypass, Off-Pump , Humans , Male , Coronary Artery Bypass, Off-Pump/adverse effects , Coronary Artery Bypass, Off-Pump/mortality , Female , Middle Aged , Aged , Likelihood Functions , Coronary Artery Bypass/adverse effects , Coronary Artery Bypass/mortality , Iran/epidemiology , Coronary Artery Disease/surgery , Coronary Artery Disease/mortality , Treatment Outcome , Propensity Score , Cardiopulmonary Bypass/adverse effects
2.
Mult Scler Relat Disord ; 75: 104765, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37209499

ABSTRACT

BACKGROUND: Epidemiological studies have shown conflicting results between antibiotic use and multiple sclerosis (MS) risks. The present systematic review and meta-analysis were conducted to assess the association between antibiotic use and the risk of MS. METHODS: PubMed, Scopus, Embase, Web of Science, and Google Scholar as well as reference lists of retrieved studies were searched systematically to identify studies were assessed the relationship between antibiotic use and MS up to September 24, 2022. Random-effects model was used for the calculation of pooled Odds ratio (OR) and 95% confidence intervals (CI). RESULTS: Five independent studies containing 47,491 participants were included in the meta-analysis. The overall results of included studies showed a non-significant positive association between antibiotic use (OR overall=1.01, 95%CI: 0.75-1.37) and a non-significant negative association between penicillin use (OR overall= 0.83; 95%CI: 0.62-1.13) and MS risk. Heterogeneity was (I2=90.1, P heterogeneity < 0.001) and (I2=90.7, P heterogeneity < 0.001) in antibiotics and penicillin use groups respectively. CONCLUSION: Our meta-analysis did not show a significant association between antibiotic or penicillin use with the risk of MS. However, due to the limitations of this study, further well-designed studies are required to confirm our findings.


Subject(s)
Anti-Bacterial Agents , Multiple Sclerosis , Humans , Anti-Bacterial Agents/adverse effects , Multiple Sclerosis/drug therapy , Multiple Sclerosis/epidemiology , Penicillins , Odds Ratio
3.
Diabetes Metab Syndr ; 14(5): 1101-1108, 2020.
Article in English | MEDLINE | ID: mdl-32653635

ABSTRACT

BACKGROUND AND AIMS: Non communicable diseases including diabetes imposes substantial financial burden on households, societies and nations in both developed and developing countries. However, there is no information on the extent of diabetes expenditure in the Eastern Mediterranean Region (EMRO). Therefore, this study aimed to identify the treatment costs of diabetes in this area. To our knowledge, this is the first systematic review on treatment expenditures of diabetes in EMRO countries. METHODS: A comprehensive literature search was conducted in PUBMED, MEDLINE, EMBASE, SCOPUS and WEB OF SCIENCES databases to find out published manuscripts on treatment cost of diabetes. Information was extracted using data extraction sheets and then the data were imported into STATA software version.11. Mean annual treatment cost of diabetes per patient, annual treatment costs of diabetes per patient by Diabetes Mellitus (DM) complications and finally, cost of chronic diabetes complications per patient were pooled and reported. RESULTS: After reviewing title, abstract and the full text of identified articles; a total of seven studies were reported appropriate data for this meta-analysis. The pooled annual treatment cost per diabetes patient for EMRO countries was 1150 US$ (95% CI: 595-2221) which was 3358 US$ (95% CI: 2200-5124) in EMRO countries except of Iran compared to 255 US$ (92-708) in Iran. The treatment cost of diabetes was higher in males, insulin-used and in the patient with family history of diabetes. The cost of diabetes was significantly increased with the duration of diabetes (P = 0.001) as well. According to the results, the largest share of costs is related to medication costs. Finally, the pooled average annual treatment cost per patient by diabetes mellitus complications was varied from 2828 US$ in the patients that have cerebrovascular disease complication to 7261 US$ in the patients with Stroke complication. CONCLUSIONS: This study demonstrated that the annual treatment cost of diabetes is varied within EMRO countries. Qatar and Iran have spent the highest and lowest cost for diabetes, respectively. This may be due to the large socioeconomic differences between countries and special conditions of them such as currency value in the region.


Subject(s)
Cost of Illness , Diabetes Mellitus, Type 1/economics , Diabetes Mellitus, Type 2/economics , Health Care Costs/statistics & numerical data , Hypoglycemic Agents/economics , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/epidemiology , Humans , Hypoglycemic Agents/therapeutic use , Mediterranean Region/epidemiology , Prognosis
4.
Epidemiol Health ; 40: e2018048, 2018.
Article in English | MEDLINE | ID: mdl-30336663

ABSTRACT

OBJECTIVES: Thalassemia is a common genetic disease in Iran, especially in the north and south of Iran. The present study sought to determine the survival rate of patients with thalassemia in highly endemic regions of Iran and its variation in patients born before and after 1971. METHODS: The present historical cohort study extracted data from the health records of patients with beta-thalassemia major, beta-thalassemia intermedia, and sickle beta-thalassemia who had presented to thalassemia treatment centers in the past years. The collected data were analyzed using the Kaplan-Meier test, the log-rank test, and the chi-square test. RESULTS: Of the total of 5,491 medical records (2,647 men and 2,634 women; mean age, 23.81±11.32 years), 3,936 belonged to patients with beta-thalassemia major, and 999 and 89 to patients with beta-thalassemia intermedia and sickle beta-thalassemia, respectively. In 467 cases, the type of thalassemia was not clear. The cumulative survival rate was calculated as 0.92, 0.83, 0.74, and 0.51 by ages 25, 35, 45, and 55, respectively. The hazard ratio of death was 4.22 (p<0.05) for beta-thalassemia major and 0.77 for beta-thalassemia intermedia (p=0.70). It was calculated as 1.45 for men patients and as 3.82 for single patients. CONCLUSIONS: The present study showed relatively high survival rates in patients with thalassemia. The survival of patients was unfavorable in poorer regions (Zahedan and Iranshahr). Factors including women gender, a higher level of education, being married, and living in metropolises decreased the risk of death at younger ages and improved survival.


Subject(s)
beta-Thalassemia/mortality , beta-Thalassemia/therapy , Adolescent , Adult , Child , Cohort Studies , Female , Humans , Iran/epidemiology , Male , Socioeconomic Factors , Survival Rate/trends , Young Adult , beta-Thalassemia/classification
5.
Int J Occup Saf Ergon ; 24(3): 431-437, 2018 Sep.
Article in English | MEDLINE | ID: mdl-28589778

ABSTRACT

INTRODUCTION: Most work-related musculoskeletal disorders (MSDs) are associated with improper postures and poorly designed workstations. This study is an attempt to examine the prevalence and severity of MSDs as well as anthropometric dimensions among city bus drivers. METHODOLOGY: This cross-sectional study was carried out on 60 male bus drivers. A body discomfort chart was used to evaluate MSDs. Spearman correlation was employed to examine the relationship between body size and the severity of discomfort. RESULTS: Data analysis showed that discomfort reported in the lower back (33.3%), upper back (18.3%) and knee (15%) was severe and there was a direct and significant correlation between the body mass index and the severity of discomfort in the shoulder, arm and hip (p < 0.05). However, the results showed that eye sitting height and sitting height had significant inverse relationships with discomfort in the ankle and elbow (p < 0.05). CONCLUSION: The results of the study can be used to address ergonomic risk factors and reduce their associated disorders. The findings of the study can be used in training programs to educate drivers how to decrease the risk associated with work-related MSDs by adopting appropriate behavior strategies.


Subject(s)
Anthropometry , Automobile Driving , Musculoskeletal Diseases/epidemiology , Occupational Diseases/epidemiology , Adult , Body Mass Index , Cross-Sectional Studies , Humans , Iran , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...